TEVA PHARMACEUTICAL INDUSTRIES LTD【TEVA】
時価総額
$367.1億
PER
ジェネリック・バイオシミラー・革新的医薬品の製造販売の最大手。AJOVYやAUSTEDOなどの主力製品を展開。約500品目、1,400剤型のポートフォリオ。2024年にPivot to Growth戦略実行。米国・欧州・国際市場35カ国超。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income (loss) | 3,339 | 2,768 | 1,910 | 1,253 | 3,042 | 1,597 | 311 | -16,449 | -2,472 | -1,000 | -4,099 | 456 | -2,406 | -615 | -1,959 |
| Impairment of goodwill | - | - | - | - | - | - | 900 | 17,100 | 3,027 | - | 4,628 | - | 2,045 | 700 | 1,280 |
| Impairment of long-lived assets and assets held for sale | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,275 |
| Depreciation and amortization | 977 | 1,069 | 1,708 | 1,642 | 1,508 | 1,308 | 1,524 | 2,112 | 1,842 | 1,722 | 1,557 | 1,330 | 1,308 | 1,153 | 1,059 |
| Net change in operating assets and liabilities | 253 | -597 | -414 | -968 | -290 | -967 | -1,219 | 363,000,000 | 1,823 | 896 | 2,188 | 1,701 | -1,257 | 72 | 435 |
| Deferred Income Taxes Net And Uncertain Tax Positions | -199 | -500 | -690 | -1,380 | -226 | 237 | 15 | -2,331 | -837 | -985 | -696 | -120 | -1,059 | -317 | -634 |
| Stock-based compensation | 80 | 91 | 82 | 64 | 95 | 117 | 124 | 133 | 155 | 119 | 129 | 119 | 124 | 121 | 123 |
| Net loss (gain) from sale of business and long-lived assets | - | 72 | 3 | -18 | -1 | 86 | 764 | 1,090 | 19 | 18 | 213 | -104 | -10 | 41 | 22 |
| Other items | - | - | - | - | - | 736 | - | - | - | 28 | 100 | 16 | -91 | 61 | 560 |
| Net cash provided by (used in) operating activities | 4,136 | 4,134 | 4,572 | 3,237 | 5,127 | 5,542 | 5,225 | 3,507 | 2,446 | 748 | 1,216 | 798 | 1,590 | 1,368 | 1,247 |
| Beneficial interest collected in exchange for securitized trade receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,291 |
| Purchases of property, plant and equipment and intangible assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 526 | 498 |
| Proceeds from Divestiture of Businesses | - | - | - | - | - | - | - | - | - | - | - | 311 | 68 | 68 | 43 |
| Purchases of investments and other assets | - | - | - | - | - | - | - | - | 119 | 8 | 55 | 47 | 1 | 46 | 71 |
| Proceeds from sale of investments | - | - | - | - | - | - | - | - | - | - | - | 172 | 4 | - | 40 |
| Acquisitions of businesses, net of cash acquired | 4,951 | 6,561 | - | 39 | 363 | 3,309 | 36,148 | -43 | - | - | - | - | 7 | - | 15 |
| Other investing activities | -29 | 49 | 93 | 104 | 30 | 5 | 212 | 282 | -11 | -58 | -24 | -1 | - | 5 | -2 |
| Net cash provided by (used in) investing activities | -5,455 | -7,601 | -1,134 | -1,147 | -1,450 | -5,565 | -35,740 | 2,164 | 1,866 | 1,355 | 863 | 1,523 | 656 | 968 | 792 |
| Repayment of senior notes and loans and other long term liabilities | 1,972 | 751 | 2,213 | 3,133 | 839 | 2,521 | 999 | 3,300 | 7,446 | 3,944 | 1,871 | 6,649 | 1,369 | 4,152 | 1,641 |
| Proceeds from Debt, Net of Issuance Costs | - | - | - | - | - | - | - | - | 4,434 | 2,083 | - | 4,974 | - | 2,451 | - |
| Proceeds from short term debt | - | - | - | - | - | - | - | - | - | - | 550 | 700 | - | 700 | - |
| Repayment of short term debt | - | - | - | - | - | - | - | - | - | - | 559 | 700 | - | 700 | - |
| Purchase of shares from non-controlling interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -64 |
| Dividends paid to non-controlling interests | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -78 |
| Other financing activities | - | 5 | 5 | 23 | -9 | -178 | -169 | -74 | -57 | -11 | -5 | -6 | -118 | -212 | -8 |
| Net cash provided by (used in) financing activities | 573 | 3,336 | -1,678 | -3,883 | -2,375 | 4,805 | 25,217 | -5,750 | -3,351 | -1,926 | -1,885 | -2,172 | -1,487 | -1,913 | -1,791 |
| Translation adjustment on cash and cash equivalents | - | - | - | - | - | - | - | - | -142 | 16 | 8 | -128 | -123 | -30 | -174 |
| Net change in cash, cash equivalents and restricted cash | - | - | - | - | - | - | - | - | 819 | 193 | 202 | 21 | 636 | 393 | 74 |
| Beneficial interest obtained in exchange for securitized trade receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,286 |
| Dividend Declared To Noncontrolling Interests | - | - | - | - | - | - | - | - | - | - | - | - | - | 67 | - |
| Interest | - | - | - | - | - | - | - | - | 815 | 840 | 846 | 913 | 948 | 1,078 | 1,004 |
| Income Taxes Paid, Net | 354 | 276 | 614 | 1,298 | 675 | 802 | 341 | 106 | 420 | 552 | 709 | 495 | 543 | 298 | 471 |
| Other current assets | 51 | -240 | -54 | 106 | -36 | 87 | -517 | 658 | -1,437 | -1,416 | -1,473 | -2,271 | -828 | -1,525 | -1,104 |
| Increase Decrease In Certain Current Liabilities Excluding Debt | -295 | 543 | -19 | 378 | -614 | -12 | 640 | -1,801 | -500 | 643 | -463 | 764 | 1,914 | 1,588 | 258 |
| Trade receivables net of sales reserves and allowances | -362 | 704 | 936 | 85 | 710 | 763 | 343 | 514 | 88 | -394 | -293 | -574 | 334 | 12 | 245 |
| Inventories | -16 | -762 | -511 | 399 | 230 | 129 | 372 | 199 | 26 | 271 | 41 | 380 | -163 | -147 | 166 |
| Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information | -253 | 597 | 414 | 968 | 290 | 967 | 1,219 | -363 | -1,823 | -896 | -2,188 | -1,701 | 1,257 | -72 | -435 |